211 related articles for article (PubMed ID: 23912993)
1. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
Crooke RM; Graham MJ
Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
4. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo.
Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M
Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210
[TBL] [Abstract][Full Text] [Related]
5. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
Liang XH; Sun H; Nichols JG; Crooke ST
Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
[TBL] [Abstract][Full Text] [Related]
6. Directed RNase H Cleavage of Nascent Transcripts Causes Transcription Termination.
Lai F; Damle SS; Ling KK; Rigo F
Mol Cell; 2020 Mar; 77(5):1032-1043.e4. PubMed ID: 31924447
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides.
Kashihara N; Maeshima Y; Makino H
Exp Nephrol; 1998; 6(1):84-8. PubMed ID: 9523178
[TBL] [Abstract][Full Text] [Related]
8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms.
Vickers TA; Crooke ST
PLoS One; 2014; 9(10):e108625. PubMed ID: 25299183
[TBL] [Abstract][Full Text] [Related]
10. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
12. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
[TBL] [Abstract][Full Text] [Related]
14. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
[TBL] [Abstract][Full Text] [Related]
15. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
16. An overview of sugar-modified oligonucleotides for antisense therapeutics.
Prakash TP
Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
[TBL] [Abstract][Full Text] [Related]
17. The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.
Reautschnig P; Vogel P; Stafforst T
RNA Biol; 2017 May; 14(5):651-668. PubMed ID: 27415589
[TBL] [Abstract][Full Text] [Related]
18. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
Rigo F; Seth PP; Bennett CF
Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
[TBL] [Abstract][Full Text] [Related]
20. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.
Vickers TA; Crooke ST
Nucleic Acids Res; 2015 Oct; 43(18):8955-63. PubMed ID: 26384424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]